Genmab A/S (OTCMKTS:GNMSF) Releases Earnings Results, Beats Estimates By $5.24 EPS

Genmab A/S (OTCMKTS:GNMSF) announced its quarterly earnings results on Wednesday. The company reported $5.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $5.24, Zacks reports. Genmab A/S had a return on equity of 17.73% and a net margin of 23.49%.

Genmab A/S Price Performance

Genmab A/S stock traded up $15.78 during midday trading on Friday, reaching $207.62. 30 shares of the company traded hands, compared to its average volume of 6,895. The firm has a market capitalization of $13.72 billion, a price-to-earnings ratio of 19.96 and a beta of 1.04. The business has a 50 day moving average of $206.28 and a two-hundred day moving average of $230.43. Genmab A/S has a 12 month low of $186.61 and a 12 month high of $323.02.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.